×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:RDUS

Radius Health (RDUS) Stock Forecast, Price & News

$6.12
+0.02 (+0.33%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$5.67
$6.15
50-Day Range
$5.53
$9.34
52-Week Range
$4.97
$23.00
Volume
776,632 shs
Average Volume
910,875 shs
Market Capitalization
$291.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.02
30 days | 90 days | 365 days | Advanced Chart
Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

Radius Health logo

About Radius Health

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDUS
Employees
293
Year Founded
N/A

Sales & Book Value

Annual Sales
$229.97 million
Book Value
($5.59) per share

Profitability

Net Income
$-70.18 million
Pretax Margin
-33.52%

Debt

Price-To-Earnings

Miscellaneous

Free Float
46,747,000
Market Cap
$291.13 million
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.95 out of 5 stars

Medical Sector

645th out of 1,424 stocks

Pharmaceutical Preparations Industry

302nd out of 681 stocks

Analyst Opinion: 2.8Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Radius Health (NASDAQ:RDUS) Frequently Asked Questions

Is Radius Health a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health
or view top-rated stocks.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Radius Health
.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) announced its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.19. During the same period in the previous year, the firm posted ($0.34) earnings per share.
View Radius Health's earnings history
.

What price target have analysts set for RDUS?

5 brokerages have issued 1-year price targets for Radius Health's stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate Radius Health's stock price to reach $9.60 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price.
View analysts' price targets for Radius Health
or view top-rated stocks among Wall Street analysts.

Who are Radius Health's key executives?
Radius Health's management team includes the following people:
  • Mr. G. Kelly Martin, CEO, Pres & Director (Age 63, Pay $612.37k)
  • Mr. Salvador Grausso III, Sr. VP & Head of U.S. Patient access (Age 47, Pay $530.42k)
  • Dr. Stavros C. Manolagas, Founder & Member of the Scientific Advisory Board
  • Dr. John Thomas Potts Jr., DSc, M.D., Founder & Member of the Scientific Advisory Board (Age 90)
  • Dr. Michael Rosenblatt M.D., Founder, Board Observer & Member of Scientific Advisory Board (Age 74)
  • Dr. John A. Katzenellenbogen, Founder & Member of the Scientific Advisory Board
  • Mr. Mark Conley, VP, CFO, Principal Accounting Officer & Treasurer (Age 60)
  • Mr. Peter A. Schwartzman, Head of Corp. Fin.
  • Ethan Holdaway, Head of Investor Relations
  • Ms. Kim Clarke, Gen. Counsel
What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Bellevue Group AG (17.49%), State Street Corp (8.11%), Vanguard Group Inc. (7.65%), BlackRock Inc. (7.48%), Velan Capital Investment Management LP (2.99%) and UBS Group AG (2.83%). Company insiders that own Radius Health stock include James George Chopas, Rubric Capital Management Lp and Target N V Biotech.
View institutional ownership trends for Radius Health
.

Which institutional investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wellington Management Group LLP, UBS Group AG, State Street Corp, Bank of New York Mellon Corp, Walleye Capital LLC, Walleye Capital LLC, and Simplex Trading LLC.
View insider buying and selling activity for Radius Health
or view top insider-selling stocks.

Which institutional investors are buying Radius Health stock?

RDUS stock was bought by a variety of institutional investors in the last quarter, including Velan Capital Investment Management LP, Bellevue Group AG, Acadian Asset Management LLC, Eversept Partners LP, JPMorgan Chase & Co., Assenagon Asset Management S.A., BNP Paribas Arbitrage SA, and Pinz Capital Management LP. Company insiders that have bought Radius Health stock in the last two years include Rubric Capital Management Lp, and Target N V Biotech.
View insider buying and selling activity for Radius Health
or or view top insider-buying stocks.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $6.12.

How much money does Radius Health make?

Radius Health has a market capitalization of $291.13 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70.18 million in net income (profit) each year or ($1.540010) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 293 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.